Therefore, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend targeting Hb levels of 11.0–12.0 g/dL and not greater than 13.0 g/dL in CKD patients receiving dialysis or ESA therapy without dialysis [17]. This evidence concerns the gene GSTM1 and kidney disorder.